Abstract:Objective To study the clinical features of children with Guillain-Barré syndrome (GBS) and the significance of Brighton criteria in childhood GBS. Methods A retrospective analysis was performed on the medical data of 72 children with GBS. Brighton criteria were used for the grading of diagnostic certainty (level 1 as the highest level, and level 4 as the lowest level). A Spearman's rank correlation analysis was used to evaluate the correlation of auxiliary examinations with the level of diagnostic certainty of Brighton criteria. Results A total of 72 children with GBS were enrolled, with a mean age of onset of (98±32) months. All children (100%, 72/72) had weakness of bilateral limbs and disappearance or reduction of tendon reflex, and limb weakness reached the highest level of severity within 4 weeks. Of all the 72 children, 68 (94%) had positive results of neural electrophysiological examination and 51 (71%) had positive results of cerebrospinal fluid (CSF) examination, and the positive rate of neural electrophysiological examination was significantly higher than that of CSF examination (P < 0.01). The median interval time from disease onset to neural electrophysiological examination was significantly shorter than from disease onset to CSF examination (11 days vs 14 days, P < 0.01). Of all the 72 children, 49 (68%) met Brighton criteria level 1 and 21 (29%) met Brighton criteria level 2. Neural electrophysiological examination and CSF examination were positively correlated with the level of diagnostic certainty of Brighton criteria (rs=0.953 and 0.420 respectively, P < 0.01). Conclusions Most of the children with GBS meet Brighton criteria level 1, and the positive results of CSF examination and neural electrophysiological examination play an important role in improving the level of diagnostic certainty of Brighton criteria. Neural electrophysiological examination has a higher positive rate than CSF examination in the early stage of the disease.
LIANG Ju-Fang,SUN Rui-Di,WANG Rui-Xue et al. Clinical features of children with Guillain-Barré syndrome and the significance of Brighton criteria[J]. CJCP, 2021, 23(2): 153-157.
Estrade S, Guiomard C, Fabry V, et al. Prognostic factors for the sequelae and severity of Guillain-Barré syndrome in children[J]. Muscle Nerve, 2019, 60(6):716-723.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome[J]. Ann Neurol, 1990, 27 Suppl:S21-S24.
[4]
Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and fisher syndrome:case definitions and guidelines for collection, analysis, and presentation of immunization safety data[J]. Vaccine, 2011, 29(3):599-612.
Tan CY, Razali SNO, Goh KJ, et al. Diagnosis of Guillain-Barré syndrome and validation of the Brighton criteria in Malaysia[J]. J Peripher Nerv Syst, 2020, 25(3):256-264.
[7]
Wu XJ, Shen DH, Li T, et al. Distinct clinical characteristics of pediatric Guillain-Barré syndrome:a comparative study between children and adults in Northeast China[J]. PLoS One, 2016, 11(3):e0151611.
[8]
Ye YQ, Wang KR, Sun L, et al. Clinical and electrophysiologic features of childhood Guillain-Barré syndrome in Northeast China[J]. J Formos Med Assoc, 2014, 113(9):634-639.
[9]
Bae JS, Yuki N, Kuwabara S, et al. Guillain-Barré syndrome in Asia[J]. J Neurol Neurosurg Psychiatry, 2014, 85(8):907-913.
[10]
Roodbol J, de Wit MY, van den Berg B, et al. Diagnosis of Guillain-Barré syndrome in children and validation of the Brighton criteria[J]. J Neurol, 2017, 264(5):856-861.
[11]
Wakerley BR, Uncini A, Yuki N, et al. Guillain-Barré and Miller Fisher syndromes-new diagnostic classification[J]. Nat Rev Neurol, 2014, 10(9):537-544.
[12]
Hughes RA, Newsom-Davis JM, Perkin GD, et al. Controlled trial prednisolone in acute polyneuropathy[J]. Lancet, 1978, 2(8093):750-753.
[13]
Konuşkan B, Okuyaz Ç, Taşdelen B, et al. Electrophysiological subtypes and prognostic factors of childhood Guillain-Barré syndrome[J]. Noro Psikiyatr Ars, 2018, 55(3):199-204.
[14]
Ruts L, Drenthen J, Jacobs BC, et al. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome:a prospective study[J]. Neurology, 2010, 74(21):1680-1686.
[15]
Ruts L, van Koningsveld R, van Doorn PA. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations[J]. Neurology, 2005, 65(1):138-140.
[16]
Alessandro L, Pastor Rueda JM, Wilken M, et al. Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients[J]. J Peripher Nerv Syst, 2018, 23(3):154-158.
[17]
Yosha-Orpaz N, Aharoni S, Rabie M, et al. Atypical clinical presentations of pediatric acute immune-mediated polyneuropathy[J]. J Child Neurol, 2019, 34(5):268-276.
[18]
Uncini A, Notturno F, Kuwabara S. Hyper-reflexia in Guillain-Barré syndrome:systematic review[J]. J Neurol Neurosurg Psychiatry, 2020, 91(3):278-284.
[19]
Jin J, Hu F, Qin X, et al. Very early neurophysiological study in Guillain-Barre syndrome[J]. Eur Neurol, 2018, 80(1-2):100-105.